Reblozyl Market Report 2026

Reblozyl Market Overview

• The Reblozyl market growth in the historic period has been driven by increasing prevalence of beta-thalassemia and mds, reliance on blood transfusion-based anemia management • Market expansion is supported by growing demand for transfusion-sparing therapies, expansion of biologics in hematology care • Growth Driver: The Increasing Incidence Of Myelodysplastic Syndrome (MDS) Boosts Reblozyl Market Growth • Market Trend: Innovative Solutions Focusing On The First-Line Treatments For Myelodysplastic Syndrome • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Reblozyl Market?

Reblozyl (luspatercept) is a medication used to treat anemia in patients with beta-thalassemia and myelodysplastic syndromes (MDS). It works by stimulating red blood cell production in the bone marrow. It is typically administered as an injectable therapy for patients who require regular blood transfusions. The main formulation of reblozyl is lyophilized powder for injection (25 mg, 75 mg), and subcutaneous injection. Lyophilized Powder for Injection (25 mg, 75 mg) refers to a freeze-dried form of the drug that is reconstituted with a diluent before injection, with Reblozyl formulated as a lyophilized powder for convenient storage and administration in treating anemia. It is used for indications such as beta-thalassemia, myelodysplastic syndromes (MDS), and others and distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies and utilized by hospitals, specialty clinics, and homecare settings.

What Is The Reblozyl Market Growth Forecast?

The growth in the forecast period can be attributed to growing demand for transfusion-sparing therapies, expansion of biologics in hematology care, increasing focus on long-term anemia management, rising investment in rare disease treatments, advancements in bone marrow targeting therapies. Major trends in the forecast period include increasing adoption of erythroid maturation agents, rising use of targeted anemia therapies, expansion of injectable biologic treatments, growing focus on reducing transfusion dependency, enhanced personalization of hematology care.

Global Reblozyl Market Segmentation

1) By Formulation: Lyophilized Powder For Injection (25 mg, 75 mg), Subcutaneous Injection 2) By Indication: Beta-Thalassemia, Myelodysplastic Syndromes (MDS), Other Indications 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies 4) By End-User: Hospitals, Specialty Clinics, Homecare Settings

What Are The Drivers Of The Reblozyl Market?

The increasing incidence of myelodysplastic syndrome (MDS) is expected to propel the growth of the reblozyl market going forward. Myelodysplastic syndrome is a group of disorders caused by dysfunctional blood-forming cells in the bone marrow, leading to insufficient production of healthy blood cells and potential progression to leukemia. Myelodysplastic syndrome (MDS) is primarily caused by DNA mutations in blood cells, often due to environmental factors, previous cancer treatments, or genetic disorders. Reblozyl (luspatercept) is used to treat anemia in adults with certain types of myelodysplastic syndrome (MDS) by promoting red blood cell maturation and reducing the need for transfusions. For instance, in November 2024, according to the American Cancer Society Inc., a US-based non-profit organization, the latest estimates suggest that there are between 10,000 and 15,000 new cases of myelodysplastic syndromes annually in the United States. Therefore, the increasing incidence of myelodysplastic syndrome (MDS) is driving the growth of the reblozyl industry. The growing healthcare expenditure is expected to propel the growth of the reblozyl market going forward. Healthcare expenditure refers to the total amount spent on health services and related activities within a certain period, typically measured annually. Growing healthcare expenditure is due to an aging population, chronic diseases, higher service prices, increased demand, rising drug costs, and income polarization. Increased healthcare expenditure enhances access to Reblozyl, enabling improved treatment of anemia in patients with specific blood disorders. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government agency, total healthcare expenditure rose by 5.6% in nominal terms from 2022 to 2023, compared to a growth rate of 0.9% in 2022. Additionally, total long-term health and social care expenditure increased by 2.8% in real terms in 2022. Therefore, the growing healthcare expenditure is driving the growth of the reblozyl industry.

Key Players In The Global Reblozyl Market

Major companies operating in the reblozyl market are Bristol-Myers Squibb Company and Merck & Co. Inc.

Global Reblozyl Market Trends and Insights

The key trend in the reblozyl market is focusing on developing ongoing research initiatives such as first-line treatments to gain treatment of anaemia without previous erythropoiesis-stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS). First-line treatment refers to the initial therapy recommended for a condition, typically based on effectiveness and safety consensus among experts. It is the preferred option for untreated patients, guiding subsequent treatment decisions if necessary. For instance, in August 2023, Bristol Myers Squibb Company, a US-based pharmaceutical company, announced the U.S. Food and Drug Administration (FDA) approved reblozyl (luspatercept-aamt) as a first-line treatment for anemia in adults with lower-risk myelodysplastic syndromes (MDS) who may need transfusions. This approval specifically targets adult patients with very low- to intermediate-risk MDS who have not previously been treated with erythropoiesis-stimulating agents (ESAs).

Regional Insights

North America was the largest region in the reblozyl market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Reblozyl Market?

The reblozyl market consists of sales of reblozyl (luspatercept) injection. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Reblozyl Market Report 2026?

The reblozyl market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the reblozyl industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.